Cargando…

A new aberrantly spliced BCR‐ABL1 transcript variant (e13a1) identified in routine monitoring using different quantitative reverse transcription polymerase chain reaction techniques in a patient with chronic myeloid leukemia

Quantitative reverse transcription polymerase chain reaction (qRT‐PCR) of BCR‐ABL1 transcript level is an essential part of routine disease monitoring in patients with chronic myeloid leukemia. One patient sample (e13a2 transcript detected by nested PCR) attracted attention by revealing an aberrantl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naumann, Nicole, Bross‐Bach, Ulrike, Seifarth, Wolfgang, Fabarius, Alice, Hofmann, Wolf‐Karsten, Saußele, Susanne, Spiess, Birgit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713225/ https://www.ncbi.nlm.nih.gov/pubmed/36467807 http://dx.doi.org/10.1002/jha2.553

Ejemplares similares

Reverse Transcription Can Critically Impact the Diagnostic Outcome of BCR::ABL1 Quantitative Real-Time RT-PCR
por: Spiess, Birgit, et al.
Publicado: (2023)

The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia
por: Spiess, Birgit, et al.
Publicado: (2018)

Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials
por: Spiess, Birgit, et al.
Publicado: (2019)

c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia
por: Prinzhorn, Wiltrud, et al.
Publicado: (2016)

Gene Expression Pattern of ESPL1, PTTG1 and PTTG1IP Can Potentially Predict Response to TKI First-Line Treatment of Patients with Newly Diagnosed CML
por: Christiani, Eva, et al.
Publicado: (2023)

The Proteolytic Activity of Separase in BCR-ABL-Positive Cells Is Increased by Imatinib
por: Haaß, Wiltrud, et al.
Publicado: (2012)

Separase activity distribution can be a marker of major molecular response and proliferation of CD34(+) cells in TKI-treated chronic myeloid leukemia patients
por: Spiess, Birgit, et al.
Publicado: (2020)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

BCR::ABL1 transcripts and clinical outcome ‐ interrogating the technique
por: Branford, Susan
Publicado: (2022)

Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy
por: Haaß, Wiltrud, et al.
Publicado: (2015)

Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia
por: Molica, Matteo, et al.
Publicado: (2020)

BCR-ABL1 transcript decline ratio combined BCR-ABL1(IS) as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia
por: Cai, Zhimei, et al.
Publicado: (2020)

Frequency of BCR-ABL Transcript Types in Syrian CML Patients
por: Farhat-Maghribi, Sulaf, et al.
Publicado: (2016)

Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts
por: Smith, Brittany M., et al.
Publicado: (2021)

Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells
por: Hiroki, Haruka, et al.
Publicado: (2023)

Increased separase activity and occurrence of centrosome aberrations concur with transformation of MDS
por: Ruppenthal, Sabrina, et al.
Publicado: (2018)

Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network
por: Schäfer, Vivien, et al.
Publicado: (2021)

Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients
por: Osman, Emad-Aldin I., et al.
Publicado: (2010)

Treatment-Free Remission in Chronic Myeloid Leukemia Harboring Atypical BCR-ABL1 Transcripts
por: Dragani, Matteo, et al.
Publicado: (2020)

Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
por: Massimino, Michele, et al.
Publicado: (2021)

Droplet Digital PCR for BCR–ABL1 Monitoring in Diagnostic Routine: Ready to Start?
por: Bochicchio, Maria Teresa, et al.
Publicado: (2021)

Tyrosine kinase inhibitors induce alternative spliced BCR‐ABL (Ins35bp) variant via inhibition of RNA polymerase II on genomic BCR‐ABL
por: Yuda, Junichiro, et al.
Publicado: (2020)

Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome
por: de Carvalho, Daiana Landenberger, et al.
Publicado: (2012)

Dual transcripts of BCR-ABL & different polymorphisms in chronic myeloid leukaemia patients
por: Nandagopalan, S. Rajashree, et al.
Publicado: (2016)

Two Cases of Acute Lymphoblastic Leukemia with an e1a3 BCR-ABL1 Fusion Transcript
por: Shin, Sang-Yong, et al.
Publicado: (2015)

The e8a2 fusion transcript in B lymphoblastic leukemia with BCR-ABL1 rearrangement
por: Kim, Min Jin, et al.
Publicado: (2012)

WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene
por: Montano, Giorgia, et al.
Publicado: (2015)

DNA Damage and DNA Damage Response in Chronic Myeloid Leukemia
por: Popp, Henning D., et al.
Publicado: (2020)

Erratum: Two Cases of Acute Lymphoblastic Leukemia with an e1a3 BCR-ABL1 Fusion Transcript
Publicado: (2015)

The e1a3 BCR-ABL1 Fusion Transcript in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Langabeer, Stephen E.
Publicado: (2015)

Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia
por: Gong, Z, et al.
Publicado: (2017)

Philadelphia Chromosome-positive Acute Myeloid Leukemia With e1a3 BCR-ABL1 Fusion Transcript
por: Sheets, Julia W., et al.
Publicado: (2020)

BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia
por: Paramita, Dewi Kartikawati, et al.
Publicado: (2020)

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy
por: Salmon, Matthew, et al.
Publicado: (2022)

Migrating to Long-Read Sequencing for Clinical Routine BCR-ABL1 TKI Resistance Mutation Screening
por: Schaal, Wesley, et al.
Publicado: (2022)

Targeting the PTP1B‐Bcr‐Abl1 interaction for the degradation of T315I mutant Bcr‐Abl1 in chronic myeloid leukemia
por: Elgehama, Ahmed, et al.
Publicado: (2022)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Signal Transducer and Activator of Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for Leukemogenesis
por: Nieborowska-Skorska, Malgorzata, et al.
Publicado: (1999)

A Case with Coexistence of Major and Minor BCR/ABL Fusion Transcript at Lymphoblastic Crisis of Chronic Myelogenous Leukemia in Patients with Major BCR/ABL Positivity during Chronic Phase
por: Park, Sang Hyuk, et al.
Publicado: (2013)

HERV-E-Mediated Modulation of PLA2G4A Transcription in Urothelial Carcinoma
por: Gosenca, Darko, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_lfda5ep2r6rr0n53riqae370kh